Introduction
============

Anthrax is a serious infectious disease, that mainly affects ruminants (farmed and wild animals) and can be transmitted to humans exposed to infected animals or infected products of animal origin (farmers, vets, butchers, carders, workers in the textile industry, etc.) \[[@B7]\]. The etiological agent of anthrax is *Bacillus anthracis*, a Gram-positive rod-shaped bacterium able to produce extremely resistant spores that, under unfavorable environmental conditions, can survive in the environment for several decades.

In particularly receptive animals (cattle, buffalo, sheep, goats, deer, and other wild ungulates), anthrax develops without apparent symptoms but has a fatal outcome characterized by sudden death due to acute or hyperacute septicemia and leakage of uncoagulated blood from natural openings.

In humans, anthrax can occur in three different forms with clinical signs dependent on the penetration route of the pathogen: cutaneous (generally non-fatal), pulmonary, and gastrointestinal \[[@B7]\]. Moreover, another fatal form has been described in drug users occurring after the intravenous injection of drugs contaminated with anthrax spores \[[@B2]\].

*B. anthracis* lives most of its existence in the form of a spore in soil, until ideal conditions develop allowing it to enter the reproductive cycle, which is presented mainly in domestic and wild ruminants. In animals, *B. anthracis* expresses its pathogenic activity primarily through the antiphagocytic activity of the capsule (whose genes are localized on the pXO2 plasmid) and the production of a toxic complex consisting of three proteins: protective antigen (PA), lethal factor (LF), and edema factor (EF) (whose genes are localized on the pXO1 plasmid) \[[@B7]\].

In Italy, animal anthrax is an endemic disease and most of the recorded animal outbreaks are characterized as sporadic episodes occurring usually during summer and after a rainy spring. The occurrence of new cases is generally linked to climate changes (with major incidences under warmer and extreme weather) or human activities that interfere with soil surfaces (drainage- or excavation-related work). Cases typically involve a low number of animals (one to three on average) grazing on contaminated pastures. With the exception of rare outbreaks, the disease is predominantly diffused in southern and island regions of Italy, especially in Basilicata, Apulia, and Sicily \[[@B9]\]. In Italy, over the last 50 years, about 200 outbreaks of animal anthrax have been recorded, while, more recently, between 2006 and 2017, 5 human cases of cutaneous anthrax occurred (unpublished data).

Furthermore, *B. anthracis* is considered one of the most important agents of bioterrorism. Because of its characteristics, it can be potentially misused as a biological weapon, as was confirmed by bioterrorism events in the United States in 2001 \[[@B10]\]. Due to the often-fatal outcome of human cases, quick administration of definitely effective antimicrobials is crucial either in prophylaxis, after presumptive exposure, or for therapy of clinical cases.

Materials and Methods
=====================

*B. anthracis* strains
----------------------

The *B. anthracis* strains selected for this study are members of the strain collection of the Anthrax Reference Institute of Italy (Ce.R.N.A.) located at the Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata. The selected strains were isolated in Italy between 1984 and 2017 from different outbreaks and various sources: 2 strains were isolated from two different cases of human cutaneous anthrax, 102 were isolated from animals (50 from cattle, 34 from sheep, 10 from goats, 5 from horses, 1 from donkey, 1 from deer, and 1 from a pig), and 6 were isolated from environmental samples (1 from water and 5 from soils) ([Table 1](#T1){ref-type="table"}). In addition, 3 *B. anthracis* vaccine strains were included: *B. anthracis* Sterne 34F2 (pXO1^+^, pXO2^−^), Carbosap (pXO1^+^, pXO2^+^), and Pasteur I type (pXO1^−^, pXO2^+^).

All strains have been identified and characterized to assess the presence of plasmids pXO1 and pXO2 by polymerase chain reaction (PCR) as previously described \[[@B8]\]. Moreover, all strains were genotyped by 15-loci multiple-locus variable-number of tandem repeats analysis (MLVA) as reported by Van Ert et al. \[[@B13]\]. All work involving live *B. anthracis* was performed in a biosafety level 3 laboratory within a class II safety cabinet.

Antimicrobial susceptibility testing
------------------------------------

Antimicrobial susceptibility was determined by applying a broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@B4][@B5]\]. The following most-common broad-spectrum antimicrobials, all from Acros Organics (Thermo Fisher Scientific, USA), were used at the indicated concentrations: gentamicin (0.008--16 µg/mL), streptomycin (0.015--32 µg/mL), penicillin G (0.001--2 µg/mL), amoxicillin (0.008--16 µg/mL), clindamycin (0.008--16 µg/mL), chloramphenicol (0.06--128 µg/mL), vancomycin (0.06--64 µg/mL), linezolid (0.06--64 µg/mL), erythromycin (0.008--16 µg/mL), tetracycline (0.008--16 µg/mL), ciprofloxacin (0.004--8 µg/mL), doxycycline (0.004--4 µg/mL), rifampin (0.004--8 µg/mL), cefotaxime (0.25--512 µg/mL), ceftriaxone (0.25--512 µg/mL), and trimethoprim (0.125--128 µg/mL). Each molecule was dissolved in the appropriate solvent and two-fold diluted in cation-adjusted Mueller Hinton broth (CAMHB) (BD Biosciences, USA) using microplates (100 µL/well).

Overnight cultures of each *B. anthracis* strain were suspended in sterile saline to match a 0.5 McFarland standard using a densitometer. The cell suspensions were further diluted 1:100 in CAMHB to obtain a bacterial concentration of approximately 1--5 × 10^4^ CFU/mL (CFU, colony-forming unit), and 100 µL bacterial aliquots were added to each well of the microplate.

Two microliters of a resazurin solution (6.75 mg/mL) (Sigma-Aldrich, USA) were added to each well to assess bacterial growth \[[@B11]\], and the plates were incubated overnight at 37℃. The color change caused by the resazurin was observed in the plate wells: a change from purple to pink/colorless indicated cell growth. The lowest concentration of each antibiotic that prevented bacterial growth was deemed the minimal inhibitory concentration (MIC). The use of resazurin allowed easy detection of microbial growth in extremely small solution volumes in microtiter plates; thus, there was no need for spectrophotometry of the plate samples.

The reported CLSI breakpoints (µg/mL) for *B. anthracis* were used for penicillin, amoxicillin, ciprofloxacin, doxycycline, and tetracycline while the breakpoints for *Bacillus* spp. were used for the cephem antibiotics \[[@B4]\]. Interpretative criteria for *Staphylococcus* spp. were used for gentamicin, clindamycin, chloramphenicol, vancomycin, linezolid, erythromycin, rifampin, and trimethoprim, according to CLSI guidelines \[[@B5]\]. As CLSI breakpoints for streptomycin were not available, it was not possible to give any comparable interpretation to the activity of this antimicrobial.

To check the validity of the antimicrobial susceptibility testing method, *Staphylococcus aureus* ATCC 29213 and *Escherichia coli* ATCC 25922 were tested in parallel as control strains.

Results
=======

The *B. anthracis* pX01 plasmid was not detected by PCR in five of the examined strains, including the Pasteur I type vaccine strain, whereas the pX02 plasmid of *B. anthracis* was present in all examined strains except the Sterne vaccine strain ([Table 1](#T1){ref-type="table"}). In total, 30 different genotypes were identified by the 15-loci MLVA ([Table 1](#T1){ref-type="table"}), and to each genotype, an identification number was arbitrarily attributed by Ce.R.N.A. (data not shown). The concentration that inhibited the growth of 50% (MIC~50~) and 90% (MIC~90~) of the isolates, the MIC range of each antimicrobial substance tested, and the susceptibility percentages are shown in [Table 2](#T2){ref-type="table"}.

Discussion
==========

Antimicrobial susceptibility testing has a key role in the management of anthrax infections. In this study, a total of 110 *B. anthracis* strains, isolated in Italy between 1984 and 2017 were studied to determine their susceptibility to antimicrobials. The presence of virulence factors, which were evaluated by PCR, showed that all isolates, except the Sterne vaccine strain, harbored the *capC* gene (on plasmid pXO2). The *pagA*, *lef*, and *cya* genes (on plasmid pXO1 and encoding PA, LF, and EF, respectively) were not detected in five of the tested isolates. However, it appeared that the susceptibility to antimicrobials of isolates lacking plasmids was comparable to those with both pXO1 and pXO2 plasmids.

All isolates were susceptible to most of the tested antimicrobial with the exception of trimethoprim, as expected \[[@B1]\], for which a high level of resistance was observed, whereas for ceftriaxone and cefotaxime intermediate susceptibility levels were recorded. The results are in agreement with other previously published studies \[[@B6]\]. Moreover, all 30 investigated genotypes showed no difference in antimicrobial susceptibility, probably due to the high genetic homogeneity of *B. anthracis*.

There are few reports on the antimicrobial susceptibility profiles of *B. anthracis*. This can be probably explained by the rarity of human anthrax in industrialized and developed countries, where the most of the scientific research is concentrated, by the elaboration of effective control programs over the last 50 years and by efficient therapies with well-known antimicrobials such as amoxicillin, doxycycline, ciprofloxacin, and penicillin \[[@B3][@B12]\]. The latter are the antibiotics of first choice, as recommended by the Centers for Disease Control and Prevention, for the treatment of anthrax in human cases.

In order to be effective, an antimicrobial treatment should be timely, starting immediately after infection. Healing is possible if you intervene in the initial stages of the disease, and the late administration of antibiotics is often useless. The results in the present study suggest a high degree of *in vitro* susceptibility of *B. anthracis* to many antimicrobials. The effective activity of gentamicin, streptomycin, clindamycin, chloramphenicol, vancomycin, linezolid, tetracycline, erythromycin, and rifampin, on all tested *B. anthracis* strains demonstrates several appropriate alternative antimicrobials for *B. anthracis* prophylaxis and/or treatment. All of the tested *B. anthracis* strains showed intermediate susceptibility to cephems (cefotaxime and ceftriaxone) and resistance to trimethoprim. The resistance of *B. anthracis* to trimethoprim supports a previous report of an intrinsic resistance of *B. anthracis* to this compound \[[@B1]\].

The relationship between the indications obtainable from *in vitro* tests and the real clinical efficacy of an antimicrobial is obviously not absolute and depends on a complex set of factors including the effective *in vivo* role of the microorganism and the correct modality and timing of administration of the antimicrobial, as well as the pharmacokinetic and pharmacodynamic characteristics of the antimicrobial.

Interestingly, in this study, we demonstrated that the *B. anthracis* isolates, belonging to different genotypes and isolated from different sources over a long period (1984--2017) showed the same levels of susceptibility to the tested antimicrobials. Further monitoring of the antibiotic susceptibility of *B. anthracis* is important for the identification of resistant clones and for choosing the best therapeutic strategy when an anthrax outbreak occurs.
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###### Characteristics and genotypes of the *Bacillus anthracis* strains tested in this study
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MLVA, multiple-locus variable-number of tandem repeats analysis.

###### Antibiotic susceptibilities of 110 *Bacillus anthracis* strains isolated during anthrax outbreaks in Italy
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MIC, minimal inhibitory concentration; S, susceptible; I, intermediate; R, resistant. ^\*^MIC at which 50% or 90% of tested isolates are inhibited.
